Of clinical relevance, edelfosine, a glycerophospholipid with antitumoral properties that inhibits SK3 channel activity, can inhibit migration and invasion of cancer cells in vitro and in vivo in an SK3-dependent manner, pointing towards a possible use of edelfosine in prostate cancer treatment [51–54]. Here, KCNN3 is linked to cancer.